News 04.05.2021 Zurich-Schlieren, Switzerland and Naples, Italy, May 04, 2021 – The University of Naples Federico II, Italy and Proteomedix, the Swiss cancer diagnostics company, announced today that Proclarix®, a new blood-based test for prostate cancer patient management, will be clinically evaluated and made routinely available in Italy. ”Proclarix® is an innovative decision...
News 04.05.2021 Zurich-Schlieren, Switzerland, May 04, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced today its interim management statement for the period ending March 31, 2021. “Molecular Partners continues to grow and expand the reach of...
News 23.04.2021 Zurich-Schlieren, Switzerland, April 23, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating...
News 21.04.2021 Zurich-Schlieren, Switzerland, April 21, 2021. At today's AGM of Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, the shareholders of the company approved all motions proposed by the Board of Directors with a very large...
News 12.04.2021 Zurich-Schlieren, Switzerland, April 10, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the presentation of four posters highlighting research across its immuno-oncology programs at the American Association for Cancer Research (AACR) virtual...